This quality standard covers managing prostate cancer in people referred to secondary care or having follow-up for prostate cancer in primary care. It describes high-quality care in priority areas for improvement.
We’ve produced new guidelines on delivery of systemic anticancer treatments during the COVID-19 pandemic and delivery of radiotherapy during the COVID-19 pandemic. These are relevant to statement 3 in this quality standard and may help to support using the quality standard during this time.
The quality standard does not cover recognising and referring for suspected cancer in primary care, which is covered by NICE’s quality standard on suspected cancer.
In May 2019 this quality standard was updated to reflect changes to the updated NICE guideline on prostate cancer. Statement 2 was amended so that active surveillance is an equal choice alongside prostatectomy and radiotherapy for people with low-risk localised prostate cancer. Terminology, references and links to source guidance have also been updated throughout.
How to use NICE quality standards and how we develop them
Quality standards help you improve the quality of care you provide or commission. They apply in England and Wales (see the UK government website and Welsh government website). Decisions on how they apply in Scotland and Northern Ireland are made by ministers in the Scottish government and Northern Ireland Executive.